Graft rejection after immune checkpoint inhibitor therapy in solid organ transplant recipients

Tor Magnus Smedman, Pål-Dag Line, Tormod K. Guren, Svein Dueland
  • Acta Oncologica, June 2018, Taylor & Francis
  • DOI: 10.1080/0284186x.2018.1479069

Immunotherapy in patients with a solid organ donor graft

What is it about?

Patients with solid organ donor grafts have an increased risk for developing various malignancies. Immunotherapy is used for more and more cancer types, but have not been evaluated in patients with solid organ grafts who is using immunosuppressive therapy due to the risk of graft rejection. We have collected all case reports avaliable in the literature in this review article and tried to point out which factors may contribute to graft rejection, and how to avoid them.

Read Publication

http://dx.doi.org/10.1080/0284186x.2018.1479069

The following have contributed to this page: Tor Magnus Smedman

In partnership with: